← Back to Clinical Trials
Recruiting NCT04885569

NCT04885569 Culturally Adapted Motivational Interviewing With CBT and Mindfulness Based Relapse Prevention for Substance Use Disorder in Pakistan (CAMIAB)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04885569
Status Recruiting
Phase
Sponsor Pakistan Institute of Living and Learning
Condition Substance Use Disorder (SUD)
Study Type INTERVENTIONAL
Enrollment 260 participants
Start Date 2023-12-01
Primary Completion 2025-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Motivational interviewing with CBT (MICBT)Mindfulness based Relapse Prevention (MBRP)CAMIAB

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 260 participants in total. It began in 2023-12-01 with a primary completion date of 2025-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study has both quantitative and qualitative components. The aim of study is to: 1. Culturally adapt and integrate the existing Motivational Interviewing with Cognitive Behavioral Therapy(MICBT) and Mindfulness based Relapse Prevention (MBRP) for people with Substance Use Disorder (SUD) in Pakistan 2. Test the feasibility and acceptability of the integrated intervention called CAMIAB ('CAMIAB' means success in Urdu) in a randomized control trial (RCT).

Eligibility Criteria

Inclusion Criteria * Participants with substance use disorder * Meeting DSM-V criteria for substance use disorder * Age 18 years and above * Being able to understand spoken or written Urdu * Have undergone through the process of detoxification before study intervention Exclusion Criteria • Any evidence of organic brain disease, clinically significant cooccurring medical illness or mental illness to the extent that can impede their ability to provide informed consent or engagement in the intervention.

Contact & Investigator

Central Contact

Imran Bashir Chaudhry, Prof.

✉ imran.chaudhry@pill.org.pk

📞 02135871845

Principal Investigator

Imran Bashir Chaudhry, Prof.

PRINCIPAL INVESTIGATOR

Pakistan Institute of Living and Learning

Frequently Asked Questions

Who can join the NCT04885569 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Substance Use Disorder (SUD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04885569 currently recruiting?

Yes, NCT04885569 is actively recruiting participants. Contact the research team at imran.chaudhry@pill.org.pk for enrollment information.

Where is the NCT04885569 trial being conducted?

This trial is being conducted at Lahore, Pakistan.

Who is sponsoring the NCT04885569 clinical trial?

NCT04885569 is sponsored by Pakistan Institute of Living and Learning. The principal investigator is Imran Bashir Chaudhry, Prof. at Pakistan Institute of Living and Learning. The trial plans to enroll 260 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology